Treatment of Metastatic Non-Small Cell Lung Cancer With Targeted Mutations

Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital.

In this episode, we covered:
•⁠  ⁠Common EGFR mutations and the latest treatment options, including osimertinib, amivantamab, and chemotherapy combinations.
•⁠  ⁠The importance of comprehensive NGS testing and the need for retesting at progression.
•⁠  ⁠Insights into managing side effects associated with various therapies, including the proactive management of cutaneous toxicities.
•⁠  ⁠Treatment strategies for less common mutations such as ALK, ROS1, BRAF, and RET, along with their respective targeted therapies.
•⁠  ⁠The role of immunotherapy in specific mutations and the importance of patient choice and preferences in treatment decisions.

Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice.

YouTube: https://youtu.be/LMYDAjZcn5w

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠  Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!